Nutcracker Therapeutics is developing and producing RNA therapeutics as fast as possible using microfluidic technology. RNA therapeutics have many advantages - versatility, speed, efficacy and safety. However, manufacturing has hindered the production of RNA therapeutics for multiple diseases. Through the use of their proprietary Biochip-based manufacturing platform, Nutcracker is using biochemistry, nanoparticle delivery and microfluidic engineering to automate and scale RNA therapeutics. As Nutcracker is focused on the technology, they are partnering with experts in different diseases to bring their products to patients. Currently, Nutcracker has 3 programs close to clinical trials for different cancers.

<p>Nutcracker Therapeutics is developing and producing RNA therapeutics as fast as possible using microfluidic technology. RNA therapeutics have many advantages - versatility, speed, efficacy and safety. However, manufacturing has hindered the production of RNA therapeutics for multiple diseases. Through the use of their proprietary Biochip-based manufacturing platform, Nutcracker is using biochemistry, nanoparticle delivery and microfluidic engineering to automate and scale RNA therapeutics. As Nutcracker is focused on the technology, they are partnering with experts in different diseases to bring their products to patients. Currently, Nutcracker has 3 programs close to clinical trials for different cancers.</p>


Nutcracker Therapeutics

Bioprocess Technician II - Manufacturing

CNC Machinist III

Interview: Sam Deutsch, Chief Scientific Officer, Nutcracker Therapeutics

BioSpace Movers & Shakers: SOTIO, Voyager, Nutcracker and More - BioSpace

Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform - Business Wire

We had a blast at our annual company holiday party! We're wishing everyone who celebrates a happy holiday season.

We're thrilled to announce that we are launching new CRDMO capabilities to provide next generation biomanufacturing solutions for RNA drug developers! The services will leverage our Nutcracker® Manufacturing Unit to provide flexible solutions to scale down RNA production for personalized therapeutics or scale up for clinical trials. 
Learn more here: https://lnkd.in/ent6jWrY

New COO, CBO at Nutcracker - BioCentury

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 - Business Wire

We're proud to announce that we'll be back in Boston next week as an expertise partner at the Personalized Cancer Vaccine Summit! Be sure to stop by at booth 1 to say hi! 
Learn more here: https://lnkd.in/eRa_ptpE

 Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors 

1359 NTX-0471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA expressed in-vivo biologics


              Exploring Opportunities for LNP Delivery in mRNA
            

 Rna cap analogs and methods of use 

 Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer 

Nutcracker announces key C-suite hires, unveils pipeline - The Pharma Letter

Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum - Business Wire

 Mrna treatment nanoparticles 

NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity

 Chutes & Ladders—Former Celgene CEO Alles takes the top ... 

Delivering a New “Post-COVID” Generation of RNA Therapeutics

Global mRNA Therapeutics Market Outlook Forecasts to 2030 - Spherical Insights

 Nutcracker Therapeutics' Research Partner, the University of California, San Francisco, Presents Foundational Prostate ... 

Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brands - Fierce Biotech

Nutcracker Therapeutics lays off 12 employees less than 18 months after $167M series C - Fierce Biotech

 Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology ... 

Samuel Deutsch will be presenting this week at the Personalized Cancer Vaccine Summit! His talk will focus on the manufacturing capabilities of our Nutcracker® Manufacturing Unit to create scalable and personalized medicines, including personalized cancer vaccines. 
Learn more here: https://lnkd.in/eRa_ptpE

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform - PR Newswire

Nutcracker Therapeutics Presents Precision Biomanufacturing and CRDMO Solutions at the 2024 Personalized Cancer Vaccine Summit - Yahoo Finance


              Addressing Challenges in mRNA and LNP Manufacturing (Part One)
            

Three members of our team, Samuel Deutsch, Nicole Fay, and Gad Berdugo, will be at the Personalized Cancer Vaccine Summit this week! Catch Sam's talk on Wednesday December 4 at 4:30 p.m. ET, focusing on the manufacturing capabilities of our Nutcracker® Manufacturing Unit to create scalable and personalized medicines, including personalized cancer vaccines. 
Learn more here: https://lnkd.in/eRa_ptpE

 Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the ... 

We had a great time connecting with our peers at the Personalized Cancer Vaccine Summit last week! We're proud to have sponsored such a remarkable event that provided a platform for industry leaders to communicate and share their work.

Modification of mRNA-encoded HPV16 antigens to include endolysosomal trafficking domains drives cross-presentation and results in superior in vivo and ex vivo antigen-specific responses

Why RNA Is Good For Business - Life Science Leader Magazine

 7 Companies Doing DNA Synthesis for Medical R&D 

Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers - Business Wire

Why RNA Is Good For Business

 Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer 

 Apparatuses and methods for measuring dna/rna production in biochips 

There Is a Need for Better CIN Therapies to Prevent Cervical Cancer

 Nutcracker Therapeutics Presents Precision Biomanufacturing and CRDMO Solutions at the 2024 Personalized Cancer Vaccine Summit 

Nutcracker snags $167M series C to develop 'push-button ...

 News - Business Financing, Nutcracker Therapeutics 

Biopharmaceuticals: Simplifying Complexity With mRNA - The Medicine Maker

 Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 

 The Crunchbase News Briefing: Wed., Sept. 23 

 Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer 


              Tackling The Standardization Issue For mRNA Therapeutics
            

Enhanced membrane stability of mRNA nanoparticle derived TNFSF14 results in superior T-cell and NK cell stimulation

 Nutcracker Therapeutics lays off 12 employees less than 18 months after $167M series C 

 Mrna therapies including sirp-alpha 

 Microfluidic apparatus and methods of use thereof 

Nutcracker snags $167M series C to develop 'push-button' RNA manufacturing, signs on former Gilead CFO - Fierce Biotech

Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell - Business Wire

 Nutcracker Therapeutics on LinkedIn: We are so excited that our very own Oreanna Thomas will be participating… 

 Nutcracker Therapeutics Raises $167M in Series C 

 Nutcracker raises $60M to fund 'push-button' mRNA therapeutics platform 

Longtime East Bay entrepreneur eyes streamlined RNA drugs, raises $60M - The Business Journals

Achieving Flexibility In RNA Drug Manufacturing With Microfluidics

 The Legend Steve Gorlins Golden Rules 

Top 10 RNA-Based Biopharmas - Genetic Engineering & Biotechnology News

Nutcracker: RNA Design, Delivery and Manufacturing Under One Roof

We're thrilled to be in Boston for this year's PODD conference! Colin McKinlay will be giving a talk on our peptoid-based Nutshell® delivery vehicles.

Igor Khandros and Gad Berdugo will be in Boston at the 12th International mRNA Health Conference this week! We'd love to see you there!

Local delivery of mRNA immunotherapy encoding HPV16 antigen, IL-12, and LIGHT/TNFSF14 results in superior immunogenicity and tumor clearance in a murine model of HPV16-driven cancer

134 mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory

Nutcracker Therapeutics raises $167m to advance mRNA biochip-based manufacturing platform - BioPharma-Reporter.com

 Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers 

Nutcracker Therapeutics

Business:

Drug notes:

About: